| Species |
Human |
| Protein Construction |
| hFc |
CD27 Ligand/CD70 (Gln39-Pro193)
Accession # P32970-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human CD27, His Tag at 0.5μg/ml (100μl/well) on the plate can bind CD27 Ligand/CD70 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
42.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized Human CD27, His Tag at 0.5 μg/ml (100 μL/well) on the plate. Dose response curve for CD27 Ligand/CD70 hFc Chimera, Human, hFc Tag with the EC50 of 13.3 ng/ml determined by ELISA.
CD27 Ligand/CD70 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
CD70, also named CD27 ligand (CD27L), is a type II transmembrane glycoprotein belonging to the TNF superfamily (TNFSF) and has been designated TNFSF7. CD70 is a cytokine that binds to CD27. Plays a role in T-cell activation. Induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. |
| Synonyms |
CD70 molecule; CD70; TNFSF7; CD27 Ligand; CD27-L; CD27LG; Ki-24 antigen; TNFSF7G |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
